Latest Insider Transactions at Poseida Therapeutics, Inc. (PSTX)
This section provides a real-time view of insider transactions for Poseida Therapeutics, Inc. (PSTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Poseida Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Poseida Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 08
2022
|
Eric Ostertag Director |
BUY
Open market or private purchase
|
Direct |
142,857
+14.55%
|
$428,571
$3.5 P/Share
|
|
Aug 08
2022
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
2,150,000
+15.37%
|
$6,450,000
$3.5 P/Share
|
|
Aug 03
2022
|
Eric Ostertag Director |
SELL
Open market or private sale
|
Indirect |
160,696
-100.0%
|
$482,088
$3.69 P/Share
|
|
Jun 16
2022
|
Cynthia Collins |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+50.0%
|
-
|
|
Jun 16
2022
|
Marcea Bland Lloyd |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+39.86%
|
-
|
|
Jun 16
2022
|
John P. Schmid |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+50.0%
|
-
|
|
Jun 16
2022
|
Luke Corning |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+50.0%
|
-
|
|
Jun 16
2022
|
Charles M Baum |
BUY
Grant, award, or other acquisition
|
Direct |
39,300
+50.0%
|
-
|
|
Mar 16
2022
|
Kerry D. Ingalls Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+5.17%
|
$9,000
$3.98 P/Share
|
|
Mar 01
2022
|
Brent Warner President, Gene Therapy |
BUY
Grant, award, or other acquisition
|
Direct |
307,881
+50.0%
|
-
|
|
Mar 01
2022
|
Matthew A. Spear Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+30.96%
|
-
|
|
Mar 01
2022
|
Johanna Mylet Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+37.25%
|
-
|
|
Mar 01
2022
|
Kerry D. Ingalls Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+49.02%
|
-
|
|
Mar 01
2022
|
Harry J Leonhardt GC & Chief Compliance Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Feb 01
2022
|
Eric Ostertag Director |
BUY
Grant, award, or other acquisition
|
Direct |
89,500
+11.44%
|
-
|
|
Feb 01
2022
|
Mark J Gergen President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
357,200
+50.0%
|
-
|
|
Dec 30
2021
|
Eric Ostertag Director |
SELL
Bona fide gift
|
Indirect |
48,902
-7.77%
|
-
|
|
Dec 30
2021
|
Eric Ostertag Director |
SELL
Bona fide gift
|
Direct |
93,955
-13.47%
|
-
|
|
Dec 21
2021
|
Johanna Mylet Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,716
+8.03%
|
$5,716
$1.55 P/Share
|
|
Dec 06
2021
|
Matthew A. Spear Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+13.99%
|
$10,000
$1.32 P/Share
|
|
Dec 06
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,828
+0.02%
|
$10,968
$6.9 P/Share
|
|
Dec 02
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
4,296
+0.04%
|
$25,776
$6.88 P/Share
|
|
Dec 01
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
18,365
+0.19%
|
$110,190
$6.85 P/Share
|
|
Nov 30
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
28,592
+0.3%
|
$171,552
$6.85 P/Share
|
|
Nov 29
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
11,057
+0.11%
|
$66,342
$6.89 P/Share
|
|
Nov 26
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
27,251
+0.28%
|
$163,506
$6.81 P/Share
|
|
Nov 24
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,054
+0.01%
|
$6,324
$6.89 P/Share
|
|
Nov 23
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
14,625
+0.15%
|
$87,750
$6.77 P/Share
|
|
Nov 19
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
11,104
+0.12%
|
$77,728
$7.44 P/Share
|
|
Nov 19
2021
|
Eric Ostertag Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+0.14%
|
$9,000
$9.15 P/Share
|
|
Nov 18
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
71,312
+0.74%
|
$499,184
$7.18 P/Share
|
|
Nov 17
2021
|
Kerry D. Ingalls Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$14,000
$7.0 P/Share
|
|
Nov 17
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
280,384
+2.87%
|
$1,962,688
$7.21 P/Share
|
|
Nov 16
2021
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
27,680
+0.3%
|
$193,760
$7.17 P/Share
|
|
Nov 08
2021
|
Eric Ostertag Director |
SELL
Open market or private sale
|
Indirect |
18,924
-0.27%
|
$132,468
$7.09 P/Share
|
|
Oct 11
2021
|
Eric Ostertag Director |
BUY
Exercise of conversion of derivative security
|
Direct |
18,525
+2.59%
|
$166,725
$9.15 P/Share
|
|
Oct 01
2021
|
Eric Ostertag Director |
SELL
Open market or private sale
|
Indirect |
20,029
-0.28%
|
$140,203
$7.02 P/Share
|
|
Sep 20
2021
|
Eric Ostertag Director |
SELL
Open market or private sale
|
Indirect |
20,000
-11.07%
|
$160,000
$8.0 P/Share
|
|
Sep 14
2021
|
Eric Ostertag Director |
SELL
Open market or private sale
|
Indirect |
20,000
-9.97%
|
$160,000
$8.14 P/Share
|
|
Sep 13
2021
|
Eric Ostertag Director |
BUY
Exercise of conversion of derivative security
|
Direct |
21,281
+1.54%
|
$106,405
$5.16 P/Share
|
|
Sep 09
2021
|
Matthew A. Spear Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+16.26%
|
$10,000
$1.32 P/Share
|
|
Sep 02
2021
|
Eric Ostertag Director |
SELL
Open market or private sale
|
Indirect |
61,262
-0.86%
|
$490,096
$8.34 P/Share
|
|
Sep 01
2021
|
Eric Ostertag Director |
SELL
Open market or private sale
|
Indirect |
51,149
-0.71%
|
$409,192
$8.46 P/Share
|
|
Aug 20
2021
|
Matthew A. Spear Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,000
-8.79%
|
$32,000
$8.79 P/Share
|
|
Aug 20
2021
|
Matthew A. Spear Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+8.08%
|
$4,000
$1.32 P/Share
|
|
Aug 06
2021
|
Eric Ostertag Director |
BUY
Exercise of conversion of derivative security
|
Direct |
111,149
+14.52%
|
$1,000,341
$9.15 P/Share
|
|
Aug 03
2021
|
Eric Ostertag Director |
SELL
Open market or private sale
|
Indirect |
19,936
-0.28%
|
$139,552
$7.99 P/Share
|
|
Aug 02
2021
|
Eric Ostertag Director |
SELL
Open market or private sale
|
Indirect |
13,737
-0.19%
|
$109,896
$8.13 P/Share
|
|
Jul 28
2021
|
Matthew A. Spear Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+32.53%
|
$20,000
$1.32 P/Share
|
|
Jul 02
2021
|
Eric Ostertag Director |
SELL
Open market or private sale
|
Indirect |
27,542
-0.19%
|
$247,878
$9.28 P/Share
|